

Catalog	Unit
TBI4124-5MG	5 mg
TBI4124-25MG	25 mg

Product Details

Formal Name: 4-{{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid

Alternate Names: MLN8237

Molecular Formula: C₂₇H₂₀ClFN₄O₄

Formula Weight: 518.90

CAS Number: 1028486-01-2


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 5 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.



Applications

Aurora A inhibitor

Functions

Highly potent, ATP-competitive inhibitor selective for Aurora A kinase ($K_i = 0.3$ nM; $IC_{50} = 6.7$ nM) over Aurora B ($IC_{50} = 1.5$ μ M); does not inhibit a large panel of other kinases. Also exhibits off-target binding of GABA_A ($IC_{50} = 0.49$ μ M), but no effects attributable to this binding were observed in rats. Disrupts the Aurora A / Myc complex, resulting in Myc degradation in Myc-amplified neuroblastomas. Inhibits tumor cell growth in vitro and in vivo, causing apoptosis and autophagy, disrupted mitosis, and increased chromosome alignment abnormalities.

Application Procedures

First dissolved in DMSO (up to 5 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.